Switch to: Citations

Add references

You must login to add references.
  1. The Hippocratic Bargain and Health Information Technology.Mark A. Rothstein - 2010 - Journal of Law, Medicine and Ethics 38 (1):7-13.
    Since the fourth century, B.C.E., the Oath of Hippocrates has been the starting point in analyzing the obligations of physicians to protect the privacy and confidentiality interests of their patients. The pertinent provision of the Oath reads as follows: “What I may see or hear in the course of the treatment or even outside of the treatment in regard to the life of men, which on no account must be spread abroad, I will keep to myself, holding such things shameful (...)
    Download  
     
    Export citation  
     
    Bookmark   12 citations  
  • (3 other versions)Currents in Contemporary Bioethics.Mark A. Rothstein - 2012 - Journal of Law, Medicine and Ethics 40 (2):394-400.
    Download  
     
    Export citation  
     
    Bookmark   7 citations  
  • Compelled authorizations for disclosure of health records: Magnitude and implications.Mark A. Rothstein & Meghan K. Talbott - 2007 - American Journal of Bioethics 7 (3):38 – 45.
    Each year individuals are required to execute millions of authorizations for the release of their health records as a condition of employment, applying for various types of insurance, and submitting claims for benefits. Generally, there are no restrictions on the scope of information released pursuant to these compelled authorizations, and the development of a nationwide system of interoperable electronic health records will increase the amount of health information released. After quantifying the extent of these disclosures, this article discusses why it (...)
    Download  
     
    Export citation  
     
    Bookmark   21 citations  
  • Prescription Data Mining and the Protection of Patients' Interests.David Orentlicher - 2010 - Journal of Law, Medicine and Ethics 38 (1):74-84.
    Pharmaceutical companies have long relied on direct marketing of their drugs to physicians through one-on-one meetings with sales representatives. This practice of “detailing” is substantial in its costs and its number of participants. Every year, pharmaceutical companies spend billions of dollars on millions of visits to physicians by tens of thousands of sales representatives.Critics have argued that drug detailing results in sub-optimal prescribing decisions by physicians, compromising patient health and driving up spending on medical care. In this view, physicians often (...)
    Download  
     
    Export citation  
     
    Bookmark   1 citation